Biotest gears up for 2025 financial results amid major therapy launches

Biotest is set to release its financial results for the fourth quarter and full year of 2025 on March 26, 2026. The report will highlight the impact of recent product launches, including key therapies for immune deficiencies and coagulation disorders. Meanwhile, the company continues its global expansion amid rising demand for plasma protein treatments.

In December 2025, Biotest secured U.S. approval for Fesilty, a treatment for immune deficiencies. The company plans to launch it in the American market within the first half of 2026. This follows the successful commercialisation of Yimmugo, which began U.S. distribution in October 2025 through partner Kedrion Biopharma. Yimmugo had previously received FDA approval in early 2024.

Another key product, Prufibry, gained German market approval in November 2025. Its introduction in Germany was originally scheduled for late 2025. The launch aligns with growing global demand for plasma-based therapies, which has risen by 7–10% annually since 2021. This surge is driven by an ageing population, increased chronic disease prevalence, and expanded plasma collection in emerging markets like Asia and Latin America.

Biotest's strategic moves come after Grifols acquired over 99% of its voting rights following the company's delisting from the regulated market in June 2025. The acquisition has strengthened Biotest's position in the finance sector, supporting its push into international markets.

Biotest's upcoming financial report will provide insights into the performance of its latest therapies. With Fesilty's U.S. launch imminent and Prufibry entering the German market, the company is well-positioned to meet rising demand in the stock market today. The results will also reflect the impact of Grifols' majority ownership and ongoing global expansion efforts.